HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sweeping Change At FTC May Sweep Away RCT Standard For Health Claims

This article was originally published in The Rose Sheet

Executive Summary

Confirmations by the Senate mark FTC ’s first-ever complete leadership turnover at once and fill out the roster for the first time since President Trump’s election in 2016. The agency has been operating with two commissioners since soon after the election.

You may also be interested in...



Protecting US Consumer Data Just The Tip Of Online Privacy Iceberg, Says FTC’s Slaughter

At NAD conference, Commissioner Slaughter identified “erroneous points of conventional wisdom that tend to undergird legal and policy debate about digital surveillance,” starting with privacy being “the key issue” and including “the FTC is toothless, absent new federal legislation.”

FTC Shift Under Biden Administration Begins With Chairman Simons, Senior Staff Resigning

While expected following start of Biden administration, Simon’s resignation is “somewhat of a surprise” considering it will change the balance of power to the Democrats ahead of when his term would have been ended, says advertising law attorney Ivan Wasserman.

OTC Device Claims Regulation: FTC Targets Quell On Pain Relief, FDA Warns Zona Plus On BP

An FTC member doubts NeuroMetrix crossed all FDA regulatory lines in advertising for Quell wearable pain relief technology that attorneys alleged. FDA warning letter says Zona Health executives said they “would ‘remain in all regulatory guidelines’" when the agency in 2018 explained claims violations.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS121597

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel